Clinical trials: Liver Tumor
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Carcinoma, Hepatocellular
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
- Trial name
- NCT01594125
- Testing
- Nintedanib high dose, Nintedanib low dose, Nintedanib medium dose
- Where
- 5 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Advanced Hepatocellular Carcinoma
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered…
- Trial name
- NCT02795429
- Testing
- Spartalizumab, Capmatinib
- Where
- 17 sites in Canada, China and 6 more
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Hepatocellular Cancer
Characterization of Methylation Patterns in Hepatocellular Carcinoma
This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Cirrhosis
- Trial name
- NCT04264754
- Testing
- Blood collection
- Where
- 5 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Nucleix Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Hepatocellular Carcinoma
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency…
- Trial name
- NCT00617981
- Testing
- ThermoDox, 5% Dextrose Solution
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 701 people
- Sponsor
- Imunon
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Solid Tumor, Cancer
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally…
- Conditions
- Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02705105
- Testing
- Mogamulizumab + Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Kyowa Kirin, Inc.
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Carcinoma, Hepatocellular
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
This is a multi-centre, phase II study to assess the efficacy and safety of ZD6474 in patients with Child-Pugh class A, inoperable HCC. This study comprises 2 phases, the primary treatment phase and the secondary treatment phase.
- Trial name
- NCT00508001
- Testing
- Vandetanib, Best Supportive Care
- Where
- 3 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- Genzyme, a Sanofi Company
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Primary Liver Cancer
Polyvinyl Alcohol Embolization Microspheres
To evaluate the safety and efficacy of polyvinyl alcohol embolization microspheres developed and manufactured by Shanghai Huihe Medical Technology Co., LTD.
- Trial name
- NCT05770635
- Testing
- Embosphere and chemotherapy drug, Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Shanghai Huihe Medical Technology Co., Ltd
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx